nach oben

Endocrine

Erschienen in:

09.02.2024 | Original Article

Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison’s disease

verfasst von: Katarzyna Furman, Paweł Gut, Anna Sowińska, Marek Ruchała, Marta Fichna

Erschienen in: Endocrine | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Patients receiving long-term glucocorticoid (GC) treatment are at risk of osteoporosis, while bone effects of substitution doses in Addison’s disease (AD) remain equivocal. The project was aimed to evaluate serum bone turnover markers (BTMs): osteocalcin, type I procollagen N-terminal propeptide (PINP), collagen C-terminal telopeptide (CTX), sclerostin, DKK-1 protein, and alkaline phosphatase (ALP) in relation to bone mineral density (BMD) during GC replacement.

Methods

Serum BTMs and hormones were assessed in 80 patients with AD (22 males, 25 pre- and 33 postmenopausal females) on hydrocortisone (HC) substitution for ≥3 years. Densitometry with dual-energy X-ray absorptiometry covered the lumbar spine (LS) and femoral neck (FN).

Results

Among BTMs, only PINP levels were altered in AD. BMD Z-scores remained negative except for FN in males. Considering T-scores, osteopenia was found in LS in 45.5% males, 24% young and 42.4% postmenopausal females, while osteoporosis in 9.0%, 4.0% and 21.1%, respectively. Lumbar BMD correlated positively with body mass (p = 0.0001) and serum DHEA-S (p = 9.899 × 10⁻⁶). Negative correlation was detected with HC dose/day/kg (p = 0.0320), cumulative HC dose (p = 0.0030), patient’s age (p = 1.038 × 10⁻⁵), disease duration (p = 0.0004), ALP activity (p = 0.0041) and CTX level (p = 0.0105). However, only age, body mass, ALP, serum CTX, and sclerostin remained independent predictors of LS BMD.

Conclusion

Standard HC substitution does not considerably accelerate BMD loss in AD patients and their serum BTMs: CTX, osteocalcin, sclerostin, DKK-1, and ALP activity remain within the reference ranges. Independent predictors of low lumbar spine BMD, especially ALP activity, serum CTX and sclerostin, might be monitored during GC substitution.

E.S. Husebye, B. Allolio, W. Arlt et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275(2), 104–115 (2014). https://doi.org/10.1111/joim.12162CrossRefPubMed

G. Johannsson, A. Falorni, S. Skrtic et al. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin. Endocrinol. (Oxf) 82(1), 2–11 (2015). https://doi.org/10.1111/cen.12603CrossRefPubMed

V. Guarnotta, C. Di Stefano, C. Giordano, Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency. Sci. Rep. 12(1), 13280 (2022). https://doi.org/10.1038/s41598-022-13506-5CrossRefPubMedPubMedCentral

K. Løvås, C.G. Gjesdal, M. Christensen et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone. Eur. J. Endocrinol. 160(6), 993–1002 (2009). https://doi.org/10.1530/EJE-08-0880CrossRefPubMed

M. Yazidi, C. Danguir, D. Maamer et al. Impact of hydrocortisone replacement on bone mineral density and bone turnover markers in patients with primary adrenal insufficiency. Endocr. Regul. 56(3), 209–215 (2022). https://doi.org/10.2478/enr-2022-0022CrossRefPubMed

L. Li, S. Bensing, H. Falhammar, Rate of fracture in patients with glucocorticoid replacement therapy: a systematic review and meta-analysis. Endocrine 74, 29–37 (2021). https://doi.org/10.1007/s12020-021-02723-zCrossRefPubMed

J. Compston, Glucocorticoid-induced osteoporosis: an update. Endocrine 61(1), 7–16 (2018). https://doi.org/10.1007/s12020-018-1588-2CrossRefPubMedCentral

Z.E. Belaya, T.A. Grebennikova, G.A. Melnichenko et al. Effects of endogenous hypercortisolism on bone mRNA and microRNA expression in humans. Osteoporos. Int. 29(1), 211–221 (2018). https://doi.org/10.1007/s00198-017-4241-7CrossRefPubMed

T. van Staa, H.G. Leufkens, C. Cooper, The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13(10), 777–787 (2002). https://doi.org/10.1007/s001980200108CrossRefPubMed

10.

K.R. Koetz, M. Ventz, S. Diederich, M. Quinkler, Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J. Clin. Endocrinol. Metab. 97(1), 85–92 (2012). https://doi.org/10.1210/jc.2011-2036CrossRefPubMed

11.

D.D. Chandy, E. Bhatia, Bone mineral density in patients with Addison’s disease on replacement therapy with prednisolone. Endocr. Pract. 22(4), 434–439 (2016). https://doi.org/10.4158/EP151014.ORCrossRefPubMed

12.

K.R. Frey, T. Kienitz, J. Schulz et al. Prednisolone is associated with a worse bone mineral density in primary adrenal insufficiency. Endocr. Connect. 7(6), 811–818 (2018). https://doi.org/10.1530/EC-18-0160CrossRefPubMedPubMedCentral

13.

N. Esteban, T. Loughlin, A.L. Yergey et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J. Clin. Endocrinol. Metab. 72(1), 39–45 (1991). https://doi.org/10.1210/jcem-72-1-39CrossRefPubMed

14.

W. Arlt, C. Rosenthal, S. Hahner, B. Allolio, Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin. Endocrinol. (Oxf) 64(4), 384–389 (2006). https://doi.org/10.1111/j.1365-2265.2006.02473.xCrossRefPubMed

15.

M. Fichna, M. Gryczyńska, A. Sowińska, J.Sowiński, Ocena metaboliczna terapii substytucyjnej hydrokortyzonem u pacjentów z pierwotna niedoczynnościa kory nadnerczy [Metabolic assessment of hydrocortisone replacement therapy in patients with primary adrenocortical insufficiency]. Przegl. Lek. 68(2), 96–102 (2011)PubMed

16.

V. Camozzi, C. Betterle, A.C. Frigo et al. Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison’s disease on glucocorticoid and mineralocorticoid replacement therapy. Endocrine 59(2), 319–329 (2018). https://doi.org/10.1007/s12020-017-1380-8CrossRefPubMed

17.

F. Heureux, D. Maiter, Y. Boutsen, J.P. Devogelaer, J. Jamart, J. Donckier, Evaluation de la substitution par corticostéroïdes et de ses répercussions osseuses dans la maladie d’Addison [Evaluation of corticosteroid replacement therapy and its effect on bones in Addison’s disease]. Ann. Endocrinol. (Paris) 61(3), 179–183 (2000)PubMed

18.

S. Kaptoge, L.I. Benevolenskaya, A.K. Bhalla et al. Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. Bone 36(3), 387–398 (2005). https://doi.org/10.1016/j.bone.2004.11.012CrossRefPubMed

19.

P.D. Delmas, R. Eastell, P. Garnero, M.J. Seibel, J. Stepan; Committee of Scientific Advisors of the International Osteoporosis Foundation, The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos. Int. 6, S2–S17 (2000). https://doi.org/10.1007/s001980070002CrossRef

20.

S. Vasikaran, R. Eastell, O. Bruyère et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 22(2), 391–420 (2011). https://doi.org/10.1007/s00198-010-1501-1CrossRefPubMed

21.

J. Delgado-Calle, A.Y. Sato, T. Bellido, Role and mechanism of action of sclerostin in bone. Bone 96, 29–37 (2017). https://doi.org/10.1016/j.bone.2016.10.007CrossRefPubMed

22.

P. Garnero, E. Sornay-Rendu, B. Claustrat, P.D. Delmas, Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J. Bone Miner. Res. 15(8), 1526–1536 (2000). https://doi.org/10.1359/jbmr.2000.15.8.1526CrossRefPubMed

23.

L. Gifre, S. Ruiz-Gaspà, A. Monegal et al. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Bone 57(1), 272–276 (2013). https://doi.org/10.1016/j.bone.2013.08.016CrossRefPubMed

24.

A.L. Burshell, R. Möricke, R. Correa-Rotter et al. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 46(4), 935–939 (2010). https://doi.org/10.1016/j.bone.2009.12.032CrossRefPubMed

25.

M. Tóth, A. Grossman, A. Glucocorticoid-induced osteoporosis: lessons from Cushing’s syndrome. Clin. Endocrinol. (Oxf) 79(1), 1–11 (2013). https://doi.org/10.1111/cen.12189CrossRefPubMed

26.

M.A. Valero, M. Leon, M.P. Ruiz Valdepeñas et al. Bone density and turnover in Addison’s disease: effect of glucocorticoid treatment. Bone Miner 26(1), 9–17 (1994). https://doi.org/10.1016/s0169-6009(08)80158-4CrossRefPubMed

27.

S.R. Peacey, C.Y. Guo, A.M. Robinson et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin. Endocrinol. (Oxf) 46(3), 255–261 (1997). https://doi.org/10.1046/j.1365-2265.1997.780907.xCrossRefPubMed

28.

M. Wichers, W. Springer, F. Bidlingmaier, D. Klingmüller, The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Clin. Endocrinol. (Oxf) 50(6), 759–765 (1999). https://doi.org/10.1046/j.1365-2265.1999.00723.xCrossRefPubMed

29.

A. Zdrojowy-Wełna, J. Halupczok-Żyła, N. Słoka, J. Syrycka, Ł. Gojny, M. Bolanowski, Bolanowski Trabecular bone score and sclerostin concentrations in patients with primary adrenal insufficiency. Front. Endocrinol. (Lausanne) 13, 996157 (2022). https://doi.org/10.3389/fendo.2022.996157CrossRefPubMed

30.

J.A. Kanis, L.J. Melton 3rd, C. Christiansen, C.C. Johnston, N. Khaltaev, The diagnosis of osteoporosis. J. Bone. Miner. Res. 9(8), 1137–1141 (1994). https://doi.org/10.1002/jbmr.5650090802CrossRefPubMed

31.

P. Głuszko, E. Sewerynek, W. Misiorowski et al. Guidelines for the diagnosis and management of osteoporosis in Poland. Update 2022. Endokrynol. Pol. 74(1), 5–15 (2023). https://doi.org/10.5603/EP.a2023.0012CrossRefPubMed

32.

M. Penna-Martinez, G. Meyer, A.B. Wolff et al. Vitamin D status and pathway genes in five European autoimmune Addison’s disease cohorts. Eur. J. Endocrinol. 184(3), 373–381 (2021). https://doi.org/10.1530/EJE-20-0956CrossRefPubMed

33.

W. Guo, F. Li, C. Zhu et al. Effect of hypercortisolism on bone mineral density and bone metabolism: A potential protective effect of adrenocorticotropic hormone in patients with Cushing’s disease. J. Int. Med. Res. 46(1), 492–503 (2018). https://doi.org/10.1177/0300060517725660CrossRefPubMed

34.

F.N. Ton, S.C. Gunawardene, H. Lee, R.M. Neer, Effects of low-dose prednisone on bone metabolism. J. Bone Miner. Res. 20(3), 464–470 (2005). https://doi.org/10.1359/JBMR.041125CrossRefPubMed

35.

A.M. Suliman, R. Freaney, T.P. Smith, Y. McBrinn, B. Murray, T.J. McKenna, The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency. Clin. Endocrinol. (Oxf) 59(3), 380–387 (2003). https://doi.org/10.1046/j.1365-2265.2003.01860.xCrossRefPubMed

36.

J.T. Schousboe, J.A. Shepherd, J.P. Bilezikian, S. Baim, Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J. Clin. Densitom. 16(4), 455–466 (2013). https://doi.org/10.1016/j.jocd.2013.08.004CrossRefPubMed

37.

J.P. Devogelaer, J. Crabbé, C. Nagant de Deuxchaisnes, Bone mineral density in Addison’s disease: evidence for an effect of adrenal androgens on bone mass. Br. Med. J. (Clin Res Ed 294(6575), 798–800 (1987). https://doi.org/10.1136/bmj.294.6575.798

38.

G.D. Braatvedt, M. Joyce, M. Evans, J. Clearwater, I.R. Reid, Bone mineral density in patients with treated Addison’s disease. Osteoporos. Int. 10(6), 435–440 (1999). https://doi.org/10.1007/s001980050251CrossRefPubMed

39.

E.M. Gurnell, P.J. Hunt, S.E. Curran et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 93(2), 400–409 (2008). https://doi.org/10.1210/jc.2007-1134CrossRefPubMed

40.

K. Mukaiyama, M. Kamimura, S. Uchiyama, S. Ikegami, Y. Nakamura, H. Kato, Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging Clin. Exp. Res. 27(4), 413–418 (2015). https://doi.org/10.1007/s40520-014-0296-xCrossRefPubMed

41.

A.H. van Lierop, A.W. van der Eerden, N.A. Hamdy, A.R. Hermus, M. den Heijer, S.E. Papapoulos, Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J. Clin. Endocrinol. Metab. 97(10), E1953–E1957 (2012). https://doi.org/10.1210/jc.2012-2218CrossRefPubMedPubMedCentral

42.

C. Fernández-Roldán, F. Genre, R. López-Mejías et al. Sclerostin serum levels in patients with systemic autoimmune diseases. Bonekey Rep. 5, 775 (2016). https://doi.org/10.1038/bonekey.2016.2CrossRefPubMedPubMedCentral

43.

E. Shevroja, J.Y. Reginster, O. Lamy et al. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporos. Int. 34(9), 1501–1529 (2023). https://doi.org/10.1007/s00198-023-06817-4CrossRefPubMedPubMedCentral

44.

F. Bioletto, M. Barale, M. Parasiliti-Caprino et al. Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency. Front. Endocrinol (Lausanne). 11(14), 1234237 (2023). https://doi.org/10.3389/fendo.2023.1234237CrossRef

Titel: Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison’s disease
verfasst von: Katarzyna Furman
Paweł Gut
Anna Sowińska
Marek Ruchała
Marta Fichna
Publikationsdatum: 09.02.2024
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-024-03709-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison’s disease

Abstract

Purpose

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Androgens exacerbate hepatic triglyceride accumulation in rats with polycystic ovary syndrome by downregulating MTTP expression

The diagnostic role of arginine-stimulated copeptin in the differential diagnosis of polyuria-polydipsia syndrome (PPS) in pediatric age

The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas

Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States

Association between newly diagnosed hyperglycemia/diabetes mellitus, atherogenic index of plasma and obesity in post-COVID-19 syndrome patients

The clinical signification and application value of [68Ga]Ga-PSMA imaging in thyroid malignancy

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin